Navigation Links
Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
Date:6/27/2012

eceived written Scientific Advice from the European Medicines Agency (EMA) confirming the acceptability of the Company's proposed Phase 3 design for the treatment of severe systemic lupus erythematosus patients as a basis for a marketing authorization application (MAA).  The EMA feedback confirms that our development program, including the heightened SRI-5 endpoint, is acceptable and that positive results from Phase 3 clinical studies in a severe lupus population would support approval of the product. The EMA has endorsed the Company's proposed Phase 3 manufacturing plan, which includes utilization of the recently manufactured drug substance and the use of a pre-filled syringe.

"The 200mg weekly dose was clearly the most clinically effective blisibimod dose.  In the severe lupus patients the treatment effect is evident after 12 weeks with a numerically greater number of responders at all subsequent time points despite early withdrawal of background therapy.  This is particularly evident among the most severely ill patients who require aggressive corticosteroid therapy," said Colin Hislop, M.D., Chief Medical Officer and Senior Vice President. "The PEARL-SC results demonstrate an ability to clinically differentiate blisibimod from currently available lupus therapies."

In conjunction with this press release Anthera will host a conference call at 8:30 a.m. Eastern Time tomorrow, June 28, 2012.  U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 95674621. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 95674621.  The audio replay will be available until July 5, 2012.

*SLE responder index - 5 (SRI-5) is a composite responder index evaluating various patient and physician reported clinical disease activity i
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Neuralstem Updates ALS Stem Cell Trial Progress
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
9. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
10. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Market by Equipment Type (Benchtop, Mobile, Industrial, & ... Others), Technology (Tray-style, Manifold, & Rotary) & Geography ... by MarketsandMarkets, defines and segments the lyophilization market ... regions with analyses and projections of the market ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... , , FARMINGDALE, N.Y., Jan. 11 Misonix, ... invasive ultrasonic medical device technology, which in Europe is ... other acute health conditions, has entered into a new, ... in Lima, Peru, for the distribution of the SonaStar(TM) ...
... , BETHESDA, Md., Jan. 11 Spherix Inc. (Nasdaq: ... a provider of technical and regulatory consulting services to food, ... Dr. Robert Lodder, will be presenting at the Annual OneMedPlace ... Drake Hotel in San Francisco, CA. Dr. Lodder will ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Peru 2Misonix Announces New Distribution Agreement for Peru 3Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 2Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 3
(Date:9/20/2014)... Earlier this week, Home Depot revealed that up ... credit card information pilfered by hackers, surpassing the 40 million ... articles like this one published by Bloomberg on ... , “Most people tend to focus on how many ... to score a game,” says Joe Caruso, founder and CEO/CTO ...
(Date:9/20/2014)... Final Cut Pro X Plugin developers from ... theme for FCPX filmmakers. , “Fun, cool, and simple are ... says Christina Austin, CEO of Pixel Film Studios. “It has ... features easy to use controls that give the user the ... background color, color of each circle outline, the position of ...
(Date:9/20/2014)... Everett, WA (PRWEB) September 20, 2014 “Motherhood ... Health Center of Snohomish in their latest article , ... the best that you can—and that’s what we want to ... what services they need and should expect from their Family ... the following days of new motherhood. , To learn ...
(Date:9/19/2014)... Nearly 780 Risperdal lawsuits are moving ... a meeting took place to discuss the next steps ... the court’s mass tort program. Attorneys for the plaintiffs ... at the Complex Litigation Center in Philadelphia’s City Hall ... The Risperdal lawsuits filed against Johnson & Johnson and ...
(Date:9/19/2014)... September 19, 2014 Are you tired ... of problems with seasonal allergies or sinus congestion? Fortunately, ... better alternative. , She conceived of Nose Pal ... a runny nose in public. Since it prevents nasal ... more sanitary conditions, particularly when cooking or working closely ...
Breaking Medicine News(10 mins):Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Newest Article from Community Health Center of Snohomish County Highlights The Importance of Proper Health Care for Expectant Mothers 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:Nasal Drip Eliminator Invented by InventHelp Client (LCC-218) 2
... determine how arsenic increases the risk of lung cancer ... researcher will use $1.7 million in federal funding during ... disrupt cells, leading to the disease. Chengfeng Yang, ... Medicine and MSU,s Center for Integrative Toxicology, will be ...
... National Medical Center, in partnership with The George ... and Translational Science Award (CTSA) from the National Center ... This award, which totals $20 million over ... a children,s hospital. The Clinical and Translational Science ...
... morbidly obese diabetics is causing more new cases of a ... make walking difficult or impossible, and in severe cases can ... bones with an external frame has enabled more than 90 ... University Health System foot and ankle surgeon Dr. Michael Pinzur. ...
... New and updated guidelines on recommended vitamin D intake have ... Canadian Medical Association Journal ( CMAJ ). ... of Medicine, and member of Osteoporosis Canada,s (OC) Scientific Advisory ... of Osteoporosis Canada. "OC,s current recommendations on vitamin D ...
... Kathleen Doheny HealthDay Reporter , TUESDAY, July 13 ... will last ",til death do you part" -- or if ... association game may reveal the hidden truth about your union, ... is flawed because it relies on asking the people involved ...
... common ― and often ineffective ― ways of fighting ... new study from Tel Aviv University shows why they,re ... psychologically-based smoking cessation programs. In the new study ... Dr. Reuven Dar of Tel Aviv University,s Department of ...
Cached Medicine News:Health News:Researcher targets gene regulators on link between arsenic, cancer 2Health News:Children's National Medical Center receives first NIH CTSA given to a children's hospital 2Health News:Children's National Medical Center receives first NIH CTSA given to a children's hospital 3Health News:New treatment for crippling diabetic Charcot foot 2Health News:New vitamin D guidelines 2Health News:Word Games May Predict Life of Relationship 2Health News:Word Games May Predict Life of Relationship 3Health News:Smoking mind over smoking matter 2Health News:Smoking mind over smoking matter 3
2 mm wide x 3 mm long, tapered handle. Angled 45 degrees. Round handle....
1.5 mm long blade. Square handle....
3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Medicine Products: